Whitehawk Therapeutics, Inc. (WHWK): Capital Expenditures
$552.0K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
+7.5%
3-year compound annual growth
+96.1%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $552.0K | -66.6% | 2026-03-12, From 2025-01-01 |
| 2024-12-31 | $1.65M | -58.4% | 2026-03-12, From 2024-01-01 |
| 2023-12-31 | $3.97M | +794.6% | 2025-03-28, From 2023-01-01 |
| 2022-12-31 | $444.0K | +865.2% | 2024-03-13, From 2022-01-01 |
| 2021-12-31 | $46.0K | +141.8% | 2023-03-29, From 2021-01-01 |
| 2020-12-31 | $19.0K | -92.0% | 2021-03-11, From 2020-01-01 |
| 2019-12-31 | $237.0K | +525.0% | 2021-03-11, From 2019-01-01 |
| 2018-12-31 | $37.9K | +326.2% | 2020-03-16, From 2018-01-01 |
| 2017-12-31 | $8.9K | -92.1% | 2019-03-07, From 2017-01-01 |
| 2016-12-31 | $113.3K | n/a | 2018-03-15, From 2016-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $552.0K | -66.6% |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $0 | -100.0% |
| Immunome Inc. (IMNM) | 2025-12-31 | $9.69M | +35.0% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $799.0K | -74.0% |
| Adagene Inc. (ADAG) | 2025-12-31 | $17.1K | -49.2% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $72.0K | +75.6% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $111.0K | -8.3% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $518.0K | -97.1% |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
Compare WHWK, OVID, IMNM, XENE side by side · Screen every company in Pharmaceutical Preparations ↗